Appendix A.1. Inclusion Criteria
Tumors, IIIB-IV, anaplastic lymphoma, non-small cell lung carcinoma, Gilbert syndrome
DISEASE PROGRESSION, NON-SMALL CELL LUNG CARCINOMA, BONE METASTASIS, TUMORS, ONCOLOGY, LIVER METASTASIS, GILBERT SYNDROME
For inclusion in this study, subjects were required to fulfill the following criteria:
Provision of informed consent prior to any study-specific proceduresWillingness and ability to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations, including follow-upAge ≥ 18 yearsHistologically or cytologically confirmed, locally advanced or metastatic (i.e., stage IIIB-IV not suitable for definitive concurrent chemoradiation therapy or relapsed) non-small cell lung carcinoma (NSCLC)Confirmed disease progression during or after platinum-based chemotherapy
A patient is allowed to receive one or more additional cytotoxic chemotherapyA patient with epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement should have confirmed disease progression even after the administration of approved oncogene-directed therapy prior to atezolizumabAt least one measurable lesion defined using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0–2Life expectancy ≥12 weeksThe normal function of the main organs:
WBC: >2500/mmHemoglobin: >8.0 g/dLTotal bilirubin: ≤2.5 × ULNA patient with known Gilbert syndrome with serum bilirubin ≤3 × ULN can be registeredAST, ALT, and ALP ≤2.5 × UNL, exceptions for:A patient with liver metastasis: AST and ALT ≤ 5 × ULNA patient with liver or bone metastasis: ALP ≤ 5 × ULN